APAnna D. Plyutinskaya

Anna D. Plyutinskaya

*This is an algorithmically generated author record based on publicly available information.

Anna D. Plyutinskaya has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • Nataliya B. Morozova

    Moscow Hertsen Research Institute of Oncology—Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia

    8 shared publications
  • Andrey A. Pankratov

    Department of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia

    7 shared publications
  • Ekaterina A. Plotnikova

    Department of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia

    5 shared publications
  • Maria S. Vorontsova

    Moscow Hertsen Research Institute of Oncology—Branch of the National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow 125284, Russia

    4 shared publications
  • Raisa I. Yakubovskaya

    P.A. Hertzen Moscow Institute of Oncology, 3 Vtoroi Botkinsky Proezd, 125284 Moscow, Russia

    4 shared publications
  • Andrei Dmitrievich Kaprin

    RUDN University

    3 shared publications

Latest Publications

  • PLGA Nanoparticles for Delivery of Antitumor Agents

    by E.R. Nemtsova, O.A. Bezborodova, G.V. Trunova, N.B. Morozova, A.D. Plyutinskaya, M.S. Vorontsova, Yu.B. Venediktova, V.A. Khokhlova, D. M Goshina, V.YU. Kan, et al.

    This paper presents a non-systematic review of the scientific literature focused on the study and application of nanoparticles based on the copolymer of lactic and glycolic acids (PLGA) as nanocarriers of antitumor drugs. It examines methods of manufacturing PLGA nanoparticles, their physicochemical properties which determine the accumulation of drugs, and biological properties which play an important role in the targeted delivery of antitumor drugs (passive or active). The mechanisms of passive targeting and methods of modifying the surface of nanoparticles for active targeting of drugs to tumor cells are discussed indicating possible methods of usage of PLGA nanoparticles (solid and gel-like) for patients’ treatment. The authors list main disadvantages of PLGA nanoparticles that hinder active translation of antitumor drugs inserted into nanocarriers to clinical practice. The review contains FDA recommendations from the program for study the quality of nanocarriers, including generics, with a view to ensure their transfer to clinical trials.

  • Effect of high-intensity nanosecond electromagnetic pulses on cancerous cells in vitr

    by V.A. Vdovin, A.D. Plyutinskaya, A.A. Pankratov, M.S. Vorontsova, S.A. Sapetskii, R.A. Denisov, V.A. Cherepenin

    For the purpose of evaluation of the effectiveness of nanosecond electromagnetic pulses application for the treatment of malignant neoplasms, experimental studies are conducted on Lewis lung carcinoma (LLC) cells. An equivalent electrical circuit is compiled for the pulse exposure target, which is a microplate with biological material (tumor cells) located between the electrodes of the experimental setup. The pulse transformation on the load is analyzed and a numerical evaluation of the characteristic physical quantities is performed. The results of biological experiments in vitro on the effect of nanosecond pulses on LLC tumor cells are presented, where the significant inhibition of tumor cell proliferation and an increase of efficiency with combined use with the antitumor drug Cisplatin-Teva are observed. The dependence of the cytotoxic effect on the repetition rate of the applied electrical pulses is also studied.

  • Open Access

    Combretastatins A-4 and A-1 and their derivatives: Review

    by E. R. Nemtsova, N. B. Morozova, A. D. Plyutinskaya, A. N. Noev, A. A. Pankratov, P. V. Shegay

    This modern literature review covers the results of study of the tubulin inhibitors, mainly combretastatins A-4 and A-1 (CA-4 and CA-1) or colhicinoids. The article presents data of SAR (Structure Activity Relation) study of numerous CA-4 analogues as well as mechanisms of their action evaluated in vitro (using cultured tumor cells) and in vivo (using animals with transplanted murine tumors or with xenografts of human tumors of various histogenesis). The phosphate CA-4 derivative (CA-4P) is characterized as a vascular disrupting agent (VDAs). Approaches are described for developing CA-4 analogues stable in cis-configuration as well as methods for enhancing hydrophility of promising derivatives along with retention of their high cytotoxicity. The results of various clinical trials both of CA-4P and CA-1P administered individually or in combination with chemotherapeutic drugs are also presented. Our conclusion is that despite numerous studies performed during the last thirty years no ideal water-soluble molecule with stable cis-configuration and high cytotoxic activity has been obtained which could become the basis of an active anti-tumor medicine.The aim of the review is to present the systematic data on antitumor activity of combretastatin CA-4 and CA-1 analogues as well as the modes of their modification and therapeutic usage.

  • Open Access

    PRECLINICAL STUDY OF THE PHARMACOKINETICS OF BACTERIOSENS FOR THE PHOTODYNAMIC THERAPY OF MALIGNANT NEOPLASMS

    by N. B. Morozova, E. A. Plotnikova, A. D. Plyutinskaya, V. O. Stramova, M. S. Vorontsova, A. A. Pankratov, E. A. Makarova, E. A. Lukyanets, A. D. Kaprin

    Introduction. Special attention has been recently paid to photosensitizers that absorb and fluoresce in the near infrared region of the spectrum. One of the most promising photosensitizers is bacteriosens, a synthetic bacteriochlorin derivative. Objective. To conduct a preclinical study of the biodistribution and pharmacokinetics of bacteriosens in animals.Materials and methods. The active ingredient of bacteriosens is (meso-tetra(3-pyridyl)bacteriochlorin) with of λmax 747 nm). The biodistribution and pharmacokinetics of the agent were studied in mice and rabbits. It was administered intravenously once at three doses: 1.0; 2.5 and 6.25 mg/kg for the mice and 0.236; 0.59 and 1.475 mg/kg for the rabbits. Local fluorescence spectroscopy was used for the quantitative determination of the pharmacokinetic parameters of bacteriosens.Results. Bacteriosens was removed quickly from the mouse bloodstream at 1 and 4 days after using minimal (1.0 mg/kg) and maximal (6.25 mg/kg) doses, respectively. When given at doses of 6.25 mg/kg and 1.0 mg/kg, bacteriosens was recorded in the skin, muscle, and spleen for 4 days and 24 h, respectively. The agent most intensively accumulated and long persisted in the omentum, liver, and kidneys for more than 6 days (6.25 mg/kg) and 2 days (1.0 mg/kg). A similar pattern was observed in the rabbits. Bacteriosens was rapidly removed from the rabbit bloodstream at 1 and 3 days after using at doses of 0.236 and 1.475 mg/kg, respectively. The agent was recorded in the skin, muscle, and spleen up to 4 days (1.475 mg/kg) and 3 days (0.236 mg/kg). It most intensively accumulated and long persisted in the omentum, liver, and kidneys for more than 6 days (1.475 mg/kg) and 4 days (0.236 mg/kg).Conclusion. Bacteriosens was removed from the animal bloodstream within 3–4 days after administration of the maximum dose that was 2.5 times higher than therapeutic one. The half-life of bacteriosens for mice was directly proportional to the dose and increased from 8 to 24 min; the half-life for rabbits was 20 min, irrespective of the dose. The drug was recorded in the skin for no more than 4 days. The main routes of bacteriosens elimination from the body of animals were the kidneys and liver.The study was performed in accordance with ethical principles adopted by the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes.

  • Chlorine e6 in phospholipid nanoparticles with specific targeting and penetrating peptides as prospective composition for photodynamic therapy of malignant neoplasms

    by L.V. Kostryukova, A.D. Plyutinskaya, A.A. Pankratov, E.I. Korotkevich, V.N. Prozorovskiy, E.G. Tikhonova, T.I. Torkhovskaya, Yu.A. Teryoshkina

    Cytotoxic and photoinduced activity of chlorine e6 (Ce6) in phospholipid nanoparticles with specific tumor targeting and cell-penetrating peptides was studied in vitro using human fibrosarcoma cells HT-1080. It was shown, that the binding of cell-penetrating peptide R7 - alone or combined with the peptide containing specific targeting motif NGR (Asn-Gly-Arg) - resulted in 3-fold decrease of Ce6 photoinduced activity as compared with that in nanoparticles without peptides (IC50 values were 0.7 μg/ml and 2.1 μg/ml, respectively). The NGR influence was unexpectedly low - less than 20% (IC50 1.7 μg/ml). This suggests the more importance of Ce6 cell penetration in this case, than of NGR-mediated targeting. The effect of inclusion of both peptides on the total cytotoxicity of Ce6 was minimal (10-16 times less than on the specific photoinduced activity). The obtained results - together with earlier shown effects on improvement of the pharmacokinetics of Ce6 in vivo after its embedding into phospholipid nanoparticles - indicate the prospects of using the obtained phospholipid nanoparticles system for photodynamic therapy.


  • Investigation of Ce6 accumulation and distribution in cell cultures of head and neck cancers

    by Dina Farrakhova, Yulia Maklygina, Igor Romanishkin, Anastasia Ryabova, Ilya Yakavets, Marie Millard, Lina Bolotine, Anna Plyutinskaya, Tatyana Karmakova, Andrey Pankratov, et al.

    Current paper presents the results of the chlorine e6 (Ce6) study on 2D and 3D models of FaDu cells culture. The 2D model or monolayer was used for investigation of Ce6 distribution within individual cells and their organelles. The 3D model or multicellular tumor spheroids were used for estimation of cells’ metabolic processes by the investigation of the Ce6 fluorescence distribution within spheroid's layers and Ce6 fluorescence lifetime. It was shown that 3D cell cultures and Сe6 allows estimating the cells’ metabolic processes better than in 2D monolayer cell cultures. Also, this model allows estimating the photodynamic effect depending on the proximity to the surface of different areas inside the heterogeneous 3D structure.


  • Open Access

    Solubilization of hydrophobic bacteriochlorin-based photosensitizers in micelles of surfactants

    by E. A. Plotnikova, V. O. Stramova, N. B. Morozova, A. D. Plyutinskaya, P. V. Ostroverkhov, M. A. Grin, A. F. Mironov, R. I. Yakubovskaya, A. D. Kaprin

    The aim of the paper was to obtain a stable micellar emulsion of potent photosensitizer (PS) –O-propyloxime-N-propoxybacteriopurpurinimide methyl ester absorbing light in long-wave region of the spectrum (λmax= 800±2 нм). Solubilizates of the dye based on different surfactants (Kolliphor ELP, Poloxamer 407, Emuxol 268) were obtained. Taking into account the physical and chemical parameters, the most potent micellar emulsion for injection was selected and characterized. The emulsion based on Kolliphor ELP remains stable for 4 months, with no changes in the fluorescence spectrum and absorption, as well as the particle diameter.


  • Open Access

    Preclinical trial of Bacteriosens used for the photodynamic therapyof malignant tumors, including prostate cancer

    by N. B. Morozova, E. A. Plotnikova, A. D. Plyutinskaya, V. O. Stramova, M. S. Vorontsova, A. A. Pankratov, R. I. Yakubovskaya, E. A. Makarova, E. A. Lukyanets, A. D. Kaprin

    Introduction.Bacteriochlorins are the most promising photosensitizers absorbing in the near-infrared spectral region. Their use can enhance the efficiency of photodynamic therapy due to the deeper penetration of radiation into the tumor.Objective to conduct a preclinical study of the photoinduced antitumor activity and biodistribution of Bacteriosens.Materials and methods.Bacteriosens is a preparation based on meso-tetra(3-pyridyl)bacteriochlorin absorbing at 747 nm. Photoinduced cytotoxicity was investigated in vitro using human tumor cells: A549, Hep 2, BT-474, MCF-7, SK-BR-3, PC3, and EJ and murine tumor cells: S37, C26, and LLC. In vivo studies were performed in mice with large and small tumors (S37, LLC, and C26).Results.In vitro investigation show that bacteriosens during optical irradiation led to the effective suppression of tumor cell growth in culture (the IC50 value varied from 0,08μМ to 1,21 μМ) and had no toxicity without exposure to light. The effective photodynamic therapy regimen using Bacteriosens in mice with inoculated small and large tumors of different genesis resulted in regression of a primary tumor node on 90–100 % of the animals in the absence of tumor recurrence within 90 days after treatment.Conclusion.Bacteriosens is a promising agent for the photodynamic therapy of small and large tumors; it can be successfully used as an alternative, organ-sparing minimally invasive treatment for malignant tumors, including prostate cancer.


  • Open Access

    EXPERIMENTAL CONFIRMATION FOR SELECTION OF IRRADIATION REGIMENS FOR INTRAPERITONEAL PHOTODYNAMIC THERAPY WITH PORPHYRIN AND PHTHALOCYANINE PHOTOSENSITIZERS

    by A. A. Pankratov, E. A. Suleymanov, E. A. Lukyanets, Yu. B Venediktova, A. D. Plyutinskaya

    В экспериментальных исследованиях in vitro и in vivo определены оптимальные режимы облучения для проведения интраперитонеальной фотодинамической терапии с фотосенсибилизаторами на основе порфиринов и фталоцианинов. В эксперименте на культуре клеток НЕр2 показано, что снижение плотности мощности при постоянной световой дозе достоверно приводит к увеличению эффективности фотодинамического воздействия (снижение плотности мощности с 20-80 мВт/см2 до 10 мВт/см2 позволило достигнуть такого же результата (гибель 90% клеток) при вдвое меньшей концентрации фотосенсибилизатора). Полученные результаты были подтверждены в экспериментах in vivo на мышах с перевивной опухолью S-37. При использовании световой дозы 90 Дж/см2 и плотности мощности 25 мВт/см2 ни у одного животного в экспериментальной группе не было достигнуто полной резорбции опухоли. При той же световой дозе и снижении плотности мощности до 12 мВт/см2 полная резорбция опухоли была получена у 34% животных, 66% животных погибло от фототоксического шока. При снижении световой дозы в два раза – до 45 Дж/см2, и использовании такой же низкоинтенсивной плотности мощности (12 мВт/см2) удалось добиться полной резорбции опухоли у 100% животных. В ходе дальнейших экспериментальных исследований по определению оптимального режима облучения для интраперитонеальной фотодинамической терапии была оценена реакция здоровой брюшины крыс на фотодинамическое воздействие и определены оптимальные параметры лазерного облучения, которые не вызывали некроза и выраженной воспалительной реакции брюшины – световая доза 10 Дж/см2 при плотности мощности излучения 10 мВт/см2. Таким образом, экспериментально обоснована целесообразность применения для интраперитонеальной фотодинамической терапии низкоинтенсивных режимов облучения, что позволяет достичь высокой эффективности лечения без развития воспалительной реакции брюшины.


  • Open Access

    Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer

    by Irina V Alekseenko, Eugene V Snezhkov, Igor P Chernov, Victor V Pleshkan, Victor K Potapov, Alexander V Sass, Galina S Monastyrskaya, Eugene P Kopantzev, Tatyana V Vinogradova, Yuri V Khramtsov, et al.

    Gene-directed enzyme prodrug therapy (GDEPT) represents a technology to improve drug selectivity for cancer cells. It consists of delivery into tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. Major limitations of GDEPT that hinder its clinical application include inefficient delivery into cancer cells and poor prodrug activation by suicide enzymes. We tried to overcome these constraints through a combination of suicide gene therapy with immunomodulating therapy. Viral vectors dominate in present-day GDEPT clinical trials due to efficient transfection and production of therapeutic genes. However, safety concerns associated with severe immune and inflammatory responses as well as high cost of the production of therapeutic viruses can limit therapeutic use of virus-based therapeutics. We tried to overcome this problem by using a simple nonviral delivery system. We studied the antitumor efficacy of a PEI (polyethylenimine)-PEG (polyethylene glycol) copolymer carrying the HSVtk gene combined in one vector with granulocyte–macrophage colony-stimulating factor (GM-CSF) cDNA. The system HSVtk-GM-CSF/PEI-PEG was tested in vitro in various mouse and human cell lines, ex vivo and in vivo using mouse models. We showed that the HSVtk-GM-CSF/PEI-PEG system effectively inhibited the growth of transplanted human and mouse tumors, suppressed metastasis and increased animal lifespan. We demonstrated that appreciable tumor shrinkage and metastasis inhibition could be achieved with a simple and low toxic chemical carrier – a PEI-PEG copolymer. Our data indicate that combined suicide and cytokine gene therapy may provide a powerful approach for the treatment of solid tumors and their metastases.